Update shared on 02 Dec 2025
Fair value Increased 0.69%Fosun International's analyst price target has been revised upward, increasing slightly from $5.68 to $5.72. Analysts cite marginal improvements in fair value estimates while other key metrics remain stable.
What's in the News
- Fosun International and Shanghai Fosun Pharmaceutical entered into Framework Tenancy Agreements to lease specified premises for one year, starting January 1, 2026. (Key Developments)
- A Mutual Supply Framework Agreement was established for a year beginning January 1, 2026, for the provision of medical products and services, including diagnostics, health assessments, and consulting. (Key Developments)
- A Special/Extraordinary Shareholders Meeting is scheduled on October 23, 2025, to consider approval of the 2025 H Share RSU Scheme for Fosun Pharma. (Key Developments)
Valuation Changes
- Fair Value Estimate has risen slightly from HK$5.68 to HK$5.72.
- Discount Rate remains effectively unchanged at 13.02%.
- Revenue Growth projection is stable at approximately 6.72%.
- Net Profit Margin has held steady near 2.49%.
- Future P/E ratio has increased marginally from 11.04x to 11.05x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.